Axogen, Inc. — Institutional Ownership
Which tracked institutions hold AXGN, and how they changed the position last quarter. Latest holdings as of Mar 31, 2026. Source: SEC 13-F filings.
24
Funds holding
$349033733
Total value held
Buying
18 added/new · 6 reduced
| # | Institution | Value | Shares | Δ Shares | Change (QoQ) |
|---|---|---|---|---|---|
| 1 | Blackrock, Inc. | $128241294 | 3870851 | +151414 | +4.07% |
| 2 | Morgan Stanley | $103464394 | 3122982 | +536112 | +20.72% |
| 3 | State Street Corp | $37983644 | 1146503 | +70660 | +6.57% |
| 4 | Goldman Sachs Group Inc | $19313565 | 582963 | +104404 | +21.82% |
| 5 | Bank Of America Corp /De/ | $15465880 | 466824 | -2273 | -0.48% |
| 6 | Northern Trust Corp | $13880442 | 418969 | +34695 | +9.03% |
| 7 | Invesco Ltd. | $6197261 | 189345 | +87622 | +86.14% |
| 8 | Bank Of New York Mellon Corp | $4576233 | 138130 | +3415 | +2.53% |
| 9 | Franklin Resources Inc | $3609745 | 108957 | +27527 | +33.80% |
| 10 | Raymond James Financial Inc | $3316560 | 101813 | -19790 | -16.27% |
| 11 | Principal Financial Group Inc | $2973251 | 89745 | +1210 | +1.37% |
| 12 | Sei Investments Co | $2378989 | 71808 | — | NEW BUY |
| 13 | Wells Fargo & Company/Mn | $1950297 | 59587 | +19082 | +47.11% |
| 14 | Ameriprise Financial Inc | $1909416 | 57634 | -16049 | -21.78% |
| 15 | Royal Bank Of Canada | $1822000 | 54996 | — | NEW BUY |
| 16 | Janus Henderson Group Plc | $600196 | 18100 | — | NEW BUY |
| 17 | Barclays Plc | $303272 | 9154 | — | NEW BUY |
| 18 | Pnc Financial Services Group, Inc. | $296282 | 8943 | +525 | +6.24% |
| 19 | Bank Of Montreal /Can/ | $254107 | 7670 | — | NEW BUY |
| 20 | Prudential Financial Inc | $253279 | 7645 | — | NEW BUY |
| 21 | Fifth Third Bancorp | $160415 | 4842 | -158 | -3.16% |
| 22 | Citigroup Inc | $51157 | 1563 | -3087 | -66.39% |
| 23 | Us Bancorp \De\ | $32004 | 966 | -619 | -39.05% |
| 24 | Amalgamated Financial Corp. | $50 | 6314 | — | NEW BUY |
Aggregated across tracked institutional filers. Reported quarterly on SEC Form 13-F and may lag. For research only — not investment advice.